BioTech IP Review

Modified Polynucleotides and LNP Compositions

Patent Number: US 10,703,789 B2
Filing / Priority Date: June 12, 2019
Assignees: Likely Pfizer/BioNTech collaborators (Pfizer/BioNTech use such formulations)
Title: Modified polynucleotides for the production of secreted proteins

What This Patent Covers

This patent covers:

  • Lipid Nanoparticle (LNP) formulations that encapsulate modified polynucleotides such as mRNA.
  • The LNPs include combinations of cationic lipids, neutral lipids, cholesterol, and polyethylene-glycol (PEG)-conjugated lipids designed to:
    • Protect fragile mRNA from degradation in the body.
    • Facilitate efficient delivery of genetic payloads into human cells.
    • Achieve a controlled particle size (typically 80–160 nm) optimal for in vivo uptake.

These lipid nanoparticle systems are crucial enablers of modern mRNA vaccines because raw mRNA degrades quickly and cannot enter cells without a delivery vehicle.

Why This Patent Is Important

1. Key to Ultra-Successful mRNA Vaccines

The Pfizer–BioNTech COVID-19 vaccine (Comirnaty) — one of the highest-revenue vaccines in history — relies on LNP technology to deliver nucleoside-modified mRNA encoding the SARS-CoV-2 spike protein. While the core mRNA sequence and antigen design itself are proprietary to BioNTech, the LNP delivery system protected by patents like US 10,703,789 B2 is vital to the vaccine’s performance, stability, and clinical success.

2. Foundation of mRNA Therapeutics

Beyond COVID-19, LNP platforms are a general delivery method for mRNA vaccines and therapies under development (e.g., for influenza, RSV, cancer immunotherapies). Owning strong LNP IP helps Pfizer secure broad reach in future mRNA therapeutic markets.

3. Strategic Defense in Patent Battles

LNP technology is the subject of extensive global patent litigation and licensing discussions involving Pfizer/BioNTech and other biotech companies (e.g., Moderna, Arbutus/Genevant, Bayer). These disputes center on who owns and can enforce critical delivery technology rights — underscoring the economic value of LNP patents in high-stakes vaccine markets.

Summary

Patent: US 10,703,789 B2 — Lipid nanoparticle compositions to deliver modified polynucleotide (e.g., mRNA) therapeutics
Filed: 2019
Why It Matters: This patent covers essential LNP delivery tech behind Pfizer–BioNTech’s COVID-19 vaccine platform and future mRNA medicines.

Leave a comment